Page 203 - 2019_07 resto del Mondo-web

Abnormal proplatelet formation in PT-VWD
References
1. Othman M, Kaur H, Favaloro EJ, et al. Platelet type von Willebrand disease and registry report: communication from the SSC of the ISTH. J Thromb Haemost. 2016; 14(2):411-414.
2. OrsiniS,NorisP,BuryL,etal.Bleedingrisk of surgery and its prevention in patients with inherited platelet disorders. The Surgery in Platelet disorders And Therapeutic Approach (SPATA) study. Haematologica. 2017;102(7):1192-1203.
3. SuvaLJ,HartmanE,DilleyJD,etal.Platelet dysfunction and a high bone mass pheno- type in a murine model of platelet-type von Willebrand disease. Am J Pathol. 2008; 172(2):430-439.
4. Casari C, Du V, Wu YP, et al. Accelerated uptake of VWF/platelet complexes in macrophages contributes to VWD type 2B- associated thrombocytopenia. Blood. 2013; 122(16):2893-2902.
5. Balduini A, Pallotta I, Malara A, et al. Adhesive receptors, extracellular proteins and myosin IIA orchestrate proplatelet for- mation by human megakaryocytes. J Thromb Haemost. 2008;6(11):1900-1907.
6. Balduini A, Malara A, Balduini CL, Noris P. Megakaryocytes derived from patients with the classical form of Bernard-Soulier syndrome show no ability to extend pro- platelets in vitro. Platelets. 2011;22(4):308- 311.
7. Balduini A, Malara A, Pecci A, et al. Proplatelet formation in heterozygous Bernard-Soulier syndrome type Bolzano. J Thromb Haemost. 2009;7(3):478-484.
8. Dütting S, Gaits-Iacovoni F, Stegner D, et al. A Cdc42/RhoA regulatory circuit down- stream of glycoprotein Ib guides transendothelial platelet biogenesis. Nat Commun. 2017;8:15838.
9. Nurden P, Gobbi G, Nurden A, et al. Abnormal VWF modifies megakaryocy- topoiesis: studies of platelets and megakaryocyte cultures from patients with von Willebrand disease type 2B. Blood. 2010;115(13):2649-2656.
10. Dunois-Lardé C, Capron C, Fichelson S, Bauer T, Cramer-Bordé E, Baruch D. Exposure of human megakaryocytes to high shear rates accelerates platelet produc- tion. Blood. 2009;114(9):1875-1883.
11. Poirault-Chassac S, Nguyen KA, Pietrzyk A, et al. Terminal platelet production is reg- ulated by von Willebrand factor. PLoS One. 2013;8(5):e63810.
12. Nurden P, Debili N, Vainchenker W, et al. Impaired megakaryocytopoiesis in type 2B von Willebrand disease with severe throm- bocytopenia. Blood. 2006;108(8):2587- 2595.
13. Malara A, Balduini A. Blood platelet pro- duction and morphology. Thromb Res. 2012;129(3):241-244.
14. Chang Y, Auradé F, Larbret F, et al. Proplatelet formation is regulated by the Rho/ROCK pathway. Blood. 2007; 109(10):4229-4236.
15. Semeniak D, Kulawig R, Stegner D, et al. Proplatelet formation is selectively inhibit- ed by collagen type I through Syk-indepen- dent GPVI signaling. J Cell Sci. 2016; 129(18):3473-3484.
16. Senis YA, Mazharian A, Mori J. Src family kinases: at the forefront of platelet activa- tion Blood. 2014; 124(13):2013-2024.
17. Sabri S, Foudi A, Boukour S, et al. Deficiency in the Wiskott-Aldrich protein induces premature proplatelet formation and platelet production in the bone mar- row compartment. Blood. 2006;108(1):134- 140.
18. Pecci A, Malara A, Badalucco S, et al. Megakaryocytes of patients with MYH9- related thrombocytopenia present an altered proplatelet formation. Thromb Haemost. 2009;102(1):90-96.
19. Guerrero JA, Kyei M, Russell S, et al. Visualizing the von Willebrand factor/gly- coprotein Ib-IX axis with a platelet-type
Platelet amyloid precursor protein is a mod- ulator of venous thromboembolism in mice. Blood. 2017;130(4):527-536.
29. Balduini CL, Cattaneo M, Fabris F, et al. Inherited thrombocytopenias: a proposed diagnostic algorithm from the Italian Gruppo di Studio delle Piastrine. Haematologica. 2003;88(5):582-592.
30. Kauskot A, Poirault-Chassac S, Adam F, et al. LIM kinase/cofilin dysregulation pro- motes macrothrombocytopenia in severe von Willebrand disease-type 2B. JCI Insight. 2016;1(16):e88643.
31. Noris P, Biino G, Pecci A, et al. Platelet diameters in inherited thrombocytopenias: analysis of 376 patients with all known dis- orders. Blood. 2014;124(6):e4-e10
32. Kaur H, Corscadden K, Ware J, Othman M. Thrombocytopathy leading to impaired in vivo haemostasis and thrombosis in platelet type von Willebrand disease. Thromb Haemost. 2017;117(3):543-555.
33. Falati S, Edmead CE, Poole AW. Glycoprotein Ib-V-IX, a receptor for von Willebrand factor, couples physically and functionally to the Fc receptor g-chain, Fyn, and Lyn to activate human platelets. Blood. 1999;94(5):1648-1656.
34. Maxwell MJ, Yuan Y, Anderson KE, Hibbs ML, Salem HH, Jackson SP. SHIP1 and Lyn kinase negatively regulate integrin alpha IIb beta 3 signaling in platelets. J Biol Chem. 2004;279(31):32196-32204.
35. Severin S, Nash CA, Mori J, et al. Distinct and overlapping functional roles of Src fam- ily kinases in mouse platelets. J Thromb Haemost. 2012;10(8):1631-1645.
36. Nakata Y, Tomkowicz B, Gewirtz AM, Ptasznik A. Integrin inhibition through Lyn-dependent cross talk from CXCR4 chemokine receptors in normal human CD34+ marrow cells. Blood. 2006; 107(11):4234-4239.
37. Pereira S, Lowell C. The Lyn tyrosine kinase negatively regulates neutrophil inte- grin signaling. J Immunol. 2003; 171(3):1319-1327.
38. Federici AB, Mannucci PM, Castaman G, et al. Clinical and molecular predictors of thrombocytopenia and risk of bleeding in patients with von Willebrand disease type 2B: a cohort study of 67 patients. Blood. 2009; 113(3):526-534.
39. O'Connor D, Lester W, Willoughby S, Wilde JT. Pregnancy in platelet-type VWD: a case series. Thromb Haemost. 2011; 106(2):386-387.
40. Gresele P, Falcinelli E, Bury L. Inherited platelet function disorders. Diagnostic approach and management. Hamostaseologie. 2016;36(4):265-278.
41. Sánchez-Luceros A, Woods AI, Bermejo E, et al. PT-VWD posing diagnostic and thera- peutic challenges – small case series. Platelets. 2017;28(5):484-490.
von Willebrand disease
2009;114(27):5541-5546. 20. Giannini S, Cecchetti L, Gresele P. Diagnosis of Willebrand disease by
mutation. Blood.
Mezzasoma AM, platelet-type von flow cytometry.
Haematologica. 2010;95(6):1021-1024.
21. Bury L, Malara A, Gresele P, Balduini A. Outside-in signalling generated by a consti- tutively activated integrin aIIbβ3 impairs proplatelet formation in human megakary-
ocytes. PLoS One. 2012;7(4):e34449.
22. Bury L, Falcinelli E, Chiasserini D, Springer TA, Italiano JE Jr, Gresele P. Cytoskeletal perturbation leads to platelet dysfunction and thrombocytopenia in Glanzmann vari-
ants. Haematologica. 2016;101(1):46-56.
23. Giannini S, Mezzasoma AM, Leone M, Gresele P. Laboratory diagnosis and moni- toring of desmopressin treatment of von Willebrand's disease by flow cytometry.
Haematologica. 2007;92(12):1647-1654.
24. Bafunno V, Bury L, Tiscia GL, et al. A novel congenital dysprothrombinemia leading to defective prothrombin maturation.
Thromb Res. 2014;134(5):1135-1141.
25. Abbonante V, Gruppi C, Rubel D, Gross O, Moratti R, Balduini A. Discoidin domain receptor 1 protein is a novel modulator of megakaryocyte-collagen interactions. J Biol
Chem. 2013;288(23):16738-16746.
26. Falcinelli E, Giannini S, Boschetti E, Gresele P. Platelets release active matrix metallopro- teinase-2 in vivo in humans at a site of vas- cular injury: lack of inhibition by aspirin. Br
J Haematol. 2007;138(2):221-230.
27. Pitchford SC, Momi S, Baglioni S, et al. Allergen induces the migration of platelets to lung tissue in allergic asthma. Am J Respir Crit Care Med. 2008;177(6):604-612.
28. Canobbio I, Visconte C, Momi S, et al.
haematologica | 2019; 104(7)
1481